Capricor Therapeutics
CAPR
#7992
Rank
$0.29 B
Marketcap
$6.36
Share price
-4.36%
Change (1 day)
-57.23%
Change (1 year)

Revenue for Capricor Therapeutics (CAPR)

Revenue in 2025 (TTM): $11.13 Million USD

According to Capricor Therapeutics 's latest financial reports the company's current revenue (TTM ) is $11.13 Million USD. In 2024 the company made a revenue of $22.27 Million USD a decrease over the revenue in the year 2023 that were of $25.17 Million USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Capricor Therapeutics from 2009 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) $11.13 M-50.02%
2024 $22.27 M-11.55%
2023 $25.17 M886.81%
2022 $2.55 M941.85%
2021 $0.24 M-21.06%
2020 $0.31 M-69.13%
2019 $1 M-39.87%
2018 $1.67 M-23.7%
2017 $2.19 M-31.33%
2016 $3.19 M-15.52%
2015 $3.77 M-9.38%
2014 $4.16 M
2013 N/A-100%
2012 $0.19 M-85.57%
2011 $1.35 M
2010 N/A
2009 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Cytokinetics
CYTK
$87.21 M 683.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
$92.14 B 827,795.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
$2.68 B 24,002.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
$2.6 M-76.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
$0 M-99.99%๐Ÿ‡บ๐Ÿ‡ธ USA